Atea Pharmaceuticals, Inc.

What they do

Atea discovers and develops novel, orally administered antivirals. Its lead pipeline includes the fixed-dose combination of bemnifosbuvir and ruzasvir (BEM/RZR) for HCV, and AT-587 for chronic HEV in immunocompromised patients. The company is currently conducting Phase 3 trials for BEM/RZR and a Phase 1 trial for AT-587.

Revenue drivers

• None — Atea is a clinical-stage company with no approved products or commercial sales; historical revenue was primarily from non-recurring collaboration and license agreements, with $351.4 million in 2021 and $48.6 million in 2020, and no revenue reported in recent years.

Recent performance

Atea reported a net loss of $158.0 million for the full year 2025 and a loss of $168.0 million in 2024. Operating cash flow was negative $132.0 million in 2025. As of June 30, 2026, cash and equivalents were $76.5 million, with total assets of $232.3 million and shareholder equity of $204.2 million. In July 2026, the company announced positive topline results from its C-BEYOND Phase 3 trial, achieving the primary endpoint of statistical non-inferiority versus sofosbuvir/velpatasvir (Epclusa).

Strategy

Atea's strategy is to develop BEM/RZR as a differentiated, pan-genotypic, 8-week HCV regimen with a low risk of drug-drug interactions and no food effect, targeting the current US HCV population. The company is also advancing AT-587 as a potential first direct-acting antiviral for HEV, where no approved therapies exist. It is scaling up CMC to provide commercial supply if approved and plans to submit an NDA for BEM/RZR in March 2027, pending Phase 3 success.

Risks

• No approved products — Atea has no commercial products or history of obtaining marketing approval, making success dependent on clinical and regulatory outcomes.
• Phase 3 execution risk — The second Phase 3 HCV trial, C-FORWARD, is still enrolling, and failure to meet endpoints would prevent NDA submission.
• Clinical trial failure precedent — In September 2024, the SUNRISE-3 Phase 3 trial for COVID-19 failed its primary endpoint, demonstrating the risk of late-stage failures.
• Cash burn and dilution risk — Persistent negative operating cash flow (~$132 million in 2025) and limited cash reserves may require additional financing, potentially diluting shareholders.

Outlook

Management expects to report topline results from the C-FORWARD Phase 3 trial in early Q1 2027, after previously targeting year-end 2026. Pending successful results, the company plans to submit an NDA to the FDA in March 2027. The AT-587 Phase 1 trial is advancing, and the company is focused on preparing for potential commercial launch.